Flow cytometric analysis of platelets type 2 diabetes mellitus reveals 'angry' platelets

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  Soma, Prashilla ^a   Swanepoel, Albe Carina ^a   du Plooy, Jeanette Noel ^a   Mqoco, Thandi ^a   Pretorius, Etheresia ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CD63 ANTIGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; PADGEM PROTEIN; BIOLOGICAL MARKER; LEUKOCYTE ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CARDIOVASCULAR DISEASE; CELL SPREADING; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PLATELET MICROPARTICLE; PSEUDOPODIUM; SCANNING ELECTRON MICROSCOPY; STRUCTURE ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ADOLESCENT; AGED; BLOOD; CYTOLOGY; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES; THROMBOCYTE; THROMBOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BIOMARKERS; BLOOD PLATELETS; DIABETES MELLITUS, TYPE 2; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; THROMBOSIS; YOUNG ADULT;

EID: 84977493981     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0373-x     Document Type: Article

References (41)

1. Alexandru N, Popov D, Georgescu A. Platelet dysfunction in vascular pathologies and how can it be treated. Thromb Res. 2012;129(2):116-26.
2. George JN. Platelets. Lancet. 2000;355(9214):1531-9.
3. Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J. 2001;22(17):1561-71.
4. Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, de Gaetano G. Platelet-leukocyte interactions in thrombosis. Thromb Res. 2012;129(3):263-6.
5. Ghoshal K, Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Sci World J. 2014;2014:781857.
6. Shi G, Morrell CN. Platelets as initiators and mediators of inflammation at the vessel wall. Thromb Res. 2011;127(5):387-90.
7. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003;23(12):2131-7.
8. Balasubramaniam K, Viswanathan GN, Marshall SM, Zaman AG. Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract. 2012;2012:909154.
9. Padmavathi P, Reddy VD, Maturu P, Varadacharyulu N. Smoking-induced alterations in platelet membrane fluidity and Na(+)/K(+)-ATPase activity in chronic cigarette smokers. J Atheroscler Thromb. 2010;17(6):619-27.
10. Greaves M. Coagulation abnormalities and cerebral infarction. J Neurol Neurosurg Psychiatry. 1993;56(5):433-9.
11. ® study. Cardiovasc Diabetol. 2015;14(1):86.
12. Muller KA, Chatterjee M, Rath D, Geisler T. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD. Thromb Haemost. 2015;114(3):498-518.
13. Ed Rainger G, Chimen M, Harrison MJ, Yates CM, Harrison P, Watson SP, Lordkipanidze M, Nash GB. The role of platelets in the recruitment of leukocytes during vascular disease. Platelets. 2015;26(6):507-20.
14. Viswanathan GNZA. Cardiovascular disease in patients with type 2 diabetes mellitus. J Clin Prev Cardiol. 2013;4:185-9.
15. Saboor M, Moinuddin M, Ilyas S. Comparison of platelet CD Markers between normal individuals and untreated patients with type 2 diabetes mellitus. J Hematol Thromb Dis. 2013;2(123):2.
16. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007;262(2):157-72.
17. Vericel E, Januel C, Carreras M, Moulin P, Lagarde M. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes. 2004;53(4):1046-51.
18. Gawaz M, Reininger A, Neumann FJ. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium. Thromb Res. 1996;83(5):341-9.
19. Smith NM, Pathansali R, Bath PM. Platelets and stroke. Vasc Med. 1999;4(3):165-72.
20. Marquardt L, Ruf A, Mansmann U, Winter R, Schuler M, Buggle F, Mayer H, Grau AJ. Course of platelet activation markers after ischemic stroke. Stroke. 2002;33(11):2570-4.
21. Pittilo RM. Cigarette smoking, endothelial injury and cardiovascular disease. Int J Exp Pathol. 2000;81(4):219-30.
22. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia G, Natali A, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the working group on endothelins and endothelial factors of the European society of hypertension. J Hypertens. 2005;23(2):233-46.
23. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest. 2007;131(5):1557-66.
24. Knight-Lozano CA, Young CG, Burow DL, Hu ZY, Uyeminami D, Pinkerton KE, Ischiropoulos H, Ballinger SW. Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. Circulation. 2002;105(7):849-54.
25. Carty CS, Soloway PD, Kayastha S, Bauer J, Marsan B, Ricotta JJ, Dryjski M. Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells. J Vasc Surg. 1996;24(6):927-34.
26. Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation. 1995;92(9):2432-6.
27. Hunter KA, Garlick PJ, Broom I, Anderson SE, McNurlan MA. Effects of smoking and abstention from smoking on fibrinogen synthesis in humans. Clin Sci. 2001;100(4):459-65.
28. Al-Dahr MHS. Impact of smoking on platelet, coagulation and lipid profile in young male subjects. World Appl Sci J. 2010;11(1):118-23.
29. Pretorius E, du Plooy J, Soma P, Gasparyan AY. An ultrastructural analysis of platelets, erythrocytes, white blood cells, and fibrin network in systemic lupus erythematosus. Rheumatol Int. 2014;34(7):1005-9
30. Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest. 2004;34(3):205-9.
31. Tschoepe D, Schultheiss HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation. 1993;88(1):37-42.
32. McEver RP. P-selectin/PSGL-1 and other interactions between platelets, leukocytes and endothelium. In: Platelets, vol. 2007. San Diego: Elsevier/Academic Press; 2007. p. 231-49.
33. Hughes A, McVerry BA, Wilkinson L, Goldstone AH, Lewis D, Bloom A. Diabetes, a hypercoagulable state? Hemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haematol. 1983;69(4):254-9.
34. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost. 1991;65(5):467-73.
35. Nieuwenhuis HK, van Oosterhout JJ, Rozemuller E, van Iwaarden F, Sixma JJ. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood. 1987;70(3):838-45.
36. Kraft P, De Meyer SF, Kleinschnitz C. Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'. J Cereb Blood Flow Metab. 2012;32(10):1831-40.
37. De Meyer SF, Schwarz T, Schatzberg D, Wagner DD. Platelet glycoprotein Ibalpha is an important mediator of ischemic stroke in mice. Exp Transl Stroke Med. 2011;3:9.
38. Mu FT, Andrews RK, Arthur JF, Munday AD, Cranmer SL, Jackson SP, Stomski FC, Lopez AF, Berndt MC. A functional 14-3-3zeta-independent association of PI3-kinase with glycoprotein Ib alpha, the major ligand-binding subunit of the platelet glycoprotein Ib-IX-V complex. Blood. 2008;111(9):4580-7.
39. Blann AD, Draper Z. Platelet activation as a marker of heart attack. Clin Chim Acta. 2011;412(11-12):841-2.
40. Inoue T. Cigarette smoking as a risk factor of coronary artery disease and its effects on platelet function. Tob Induc Dis. 2004;2(1):27-33.
41. Metzelaar M, Wijngaard P, Peters P, Sixma JJ, Nieuwenhuis HK, Clevers H. CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem. 1991;266(5):3239-45.